MDT-AP-1362
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 51.96
- os_event
- false
- age_years
- 11.43
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.700364033
- umap2_2d
- 2.5609186
- umap1_3d
- 2.341100912
- umap2_3d
- -2.841011204
- umap3_3d
- -3.09111119
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+0.260
- MITOTIC_SPINDLE+0.210
- PI3K_AKT_MTOR_SIGNALING+0.200
- ADIPOGENESIS+0.190
- PROTEIN_SECRETION+0.130
- PEROXISOME+0.120
- BILE_ACID_METABOLISM+0.110
- NOTCH_SIGNALING+0.110
- APICAL_JUNCTION+0.080
- DNA_REPAIR+0.080
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.470
- ANGIOGENESIS-0.420
- E2F_TARGETS-0.420
- INFLAMMATORY_RESPONSE-0.420
- MYC_TARGETS_V1-0.420
- ALLOGRAFT_REJECTION-0.400
- COMPLEMENT-0.380
- INTERFERON_ALPHA_RESPONSE-0.350
- COAGULATION-0.340
- IL6_JAK_STAT3_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1357 | Med | Medulloblastoma | 0.920 |
| 2 | MDT-AP-0576 | Med | Medulloblastoma | 0.883 |
| 3 | MDT-AP-0402 | Med | Medulloblastoma | 0.865 |
| 4 | MDT-AP-0596 | Med | Medulloblastoma | 0.859 |
| 5 | MDT-AP-0038 | Med | Medulloblastoma | 0.857 |
| 6 | MDT-AP-0578 | Med | Medulloblastoma | 0.857 |
| 7 | MDT-AP-0550 | Med | Medulloblastoma | 0.848 |
| 8 | MDT-AP-0119 | Med | Medulloblastoma | 0.846 |
| 9 | MDT-AP-3253 | Med | Medulloblastoma | 0.842 |
| 10 | MDT-AP-1261 | Med | Medulloblastoma | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |